Fulgent Genetics stockholders approved director elections, auditor ratification, executive compensation, and the 2026 Equity Incentive Plan at the May 14, 2026 Annual Meeting.
Key takeaways
Stockholders approved Fulgent Genetics 2026 Equity Incentive Plan authorizing 2,000,000 new shares plus up to 1,500,000 from Prior Plan forfeitures.
Ming Hsieh elected with strongest support at 21,979,668 for votes; other directors received 16-17M for votes.
Deloitte & Touche LLP ratified as independent auditor for FY 2026 with 24,470,414 for votes.
Advisory approval of named executive officer compensation passed with 19,800,226 for votes.
Quorum achieved with 24,578,996 shares or 83% of 29,747,420 eligible shares present.
2026 Plan replaces 2016 Omnibus Plan; no new grants under Prior Plan post-May 14, 2026.